How and when to treat AQP4-IgG-positive NMOSD

被引：0
|
作者：
Fujihara, K. [1 ]
机构：
[1] Fukushima Med Univ, Koriyama, Fukushima, Japan
来源：
MULTIPLE SCLEROSIS JOURNAL | 2022年 / 28卷 / 3_SUPPL期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
O129
引用
收藏
页码：100 / 100
页数：1
相关论文
共 50 条
  • [1] A case report on recurrent area postrema syndrome in AQP4-IgG-positive NMOSD
    Shrestha, Ramesh
    Kharel, Ghanshyam
    [J]. OXFORD MEDICAL CASE REPORTS, 2022, 2022 (10): : 338 - 340
  • [2] Area postrema syndrome Frequency, criteria, and severity in AQP4-IgG-positive NMOSD
    Shosha, Eslam
    Dubey, Divyanshu
    Palace, Jacqueline
    Nakashima, Ichiro
    Jacob, Anu
    Fujihara, Kazuo
    Takahashi, Toshiyuki
    Whittam, Daniel
    Leite, Maria Isabel
    Misu, Tatsuro
    Yoshiki, Takai
    Messina, Silvia
    Elsone, Liene
    Majed, Masoud
    Flanagan, Eoin
    Gadoth, Avi
    Huebert, Carey
    Sagen, Jessica
    Greenberg, Benjamin M.
    Levy, Michael
    Banerjee, Aditya
    Weinshenker, Brian
    Pittock, Sean J.
    [J]. NEUROLOGY, 2018, 91 (17) : E1642 - E1651
  • [3] C3 and C4 complement levels in AQP4-IgG-positive NMOSD and in MOGAD
    Pache, Florence
    Ringelstein, Marius
    Aktas, Orhan
    Kleiter, Ingo
    Jarius, Sven
    Siebert, Nadja
    Bellmann-Strobl, Judith
    Paul, Friedemann
    Ruprecht, Klemens
    [J]. JOURNAL OF NEUROIMMUNOLOGY, 2021, 360
  • [4] Systemic inflammation response index is a useful indicator in distinguishing MOGAD from AQP4-IgG-positive NMOSD
    Wang, Lei
    Xia, Ruihong
    Li, Xiangliang
    Shan, Jingli
    Wang, Shengjun
    [J]. FRONTIERS IN IMMUNOLOGY, 2024, 14
  • [5] An Abnormally High Neutrophil-to-Lymphocyte Ratio Is Not an Independent Outcome Predictor in AQP4-IgG-Positive NMOSD
    Carnero Contentti, Edgar
    Delgado-Garcia, Guillermo
    Criniti, Juan
    Lopez, Pablo A.
    Pablo Pettinicchi, Juan
    Cristiano, Edgardo
    Miguez, Jimena
    Patricio Correa-Diaz, Edgar
    Alvarez Pucha, Marcelo Oswaldo
    Mino Zambrano, Joselyn Elizabeth
    Gomez-Figueroa, Enrique
    Rivas-Alonso, Veronica
    Flores-Rivera, Jose
    Tkachuk, Veronica
    Caride, Alejandro
    Ignacio Rojas, Juan
    [J]. FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [6] Asymptomatic spinal lesions in patients with AQP4-IgG-positive NMOSD: A real-world cohort study
    Cao, Shugang
    Zhu, Yunfei
    Wu, Xiaosan
    Du, Jing
    Xu, Si
    Cui, Ping
    Li, Qi
    Xia, Mingwu
    Xue, Qun
    Tian, Yanghua
    [J]. ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY, 2024, 11 (04): : 905 - 915
  • [7] Risk of disease relapse following COVID-19 vaccination in patients with AQP4-IgG-positive NMOSD and MOGAD
    Dinoto, Alessandro
    Sechi, Elia
    Ferrari, Sergio
    Gajofatto, Alberto
    Orlandi, Riccardo
    Solla, Paolo
    Maccabeo, Alessandra
    Maniscalco, Giorgia Teresa
    Andreone, Vincenzo
    Sartori, Arianna
    Manganotti, Paolo
    Rasia, Sarah
    Capra, Ruggero
    Mancinelli, Chiara Rosa
    Mariotto, Sara
    [J]. MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 58
  • [8] Pilot Clinical Trial of Eculizumab in AQP4-IgG-Positive NMO
    Pittock, Sean J.
    McKeon, Andrew
    Mandrekar, Jay N.
    Weinshenker, Brian G.
    Lucchinetti, Claudia F.
    Wingerchuk, Dean M.
    [J]. ANNALS OF NEUROLOGY, 2012, 72 : S116 - S116
  • [9] Myelitis features and outcomes in CNS demyelinating disorders: Comparison between multiple sclerosis, MOGAD, and AQP4-IgG-positive NMOSD
    Fadda, Giulia
    Flanagan, Eoin P.
    Cacciaguerra, Laura
    Jitprapaikulsan, Jiraporn
    Solla, Paolo
    Zara, Pietro
    Sechi, Elia
    [J]. FRONTIERS IN NEUROLOGY, 2022, 13
  • [10] Eculizumab in AQP4-IgG NMOSD
    Marignier, Romain
    Kunchok, Amy
    [J]. NEUROLOGY, 2024, 103 (09)
12345